Omnes Therapeutics

Executive Summary

Omnes Therapeutics is a Belgian biotechnology company advancing gene therapies for rare metabolic diseases, leveraging its proprietary AAV capsid engineering platform to achieve high peripheral tissue specificity and low immunogenicity. Founded in 2020, the company addresses unmet needs in lysosomal storage disorders and other rare genetic conditions, aiming to deliver durable, one-time treatments. Omnes has raised $150 million in total funding, reflecting strong investor confidence in its platform and pipeline. The company operates in the preclinical stage, focusing on optimizing its AAV vectors for efficient and safe gene delivery. Omnes's progress includes the development of several preclinical programs targeting specific lysosomal storage diseases. The company's capsid engineering approach differentiates it by potentially enabling lower doses and reduced immune responses compared to conventional AAV vectors. Upcoming milestones include the filing of an Investigational New Drug (IND) application for its lead candidate, expected within the next 12–18 months. With its experienced team and robust financial backing, Omnes is well-positioned to advance toward clinical development, though its success hinges on demonstrating preclinical proof-of-concept and eventual clinical validation.

Upcoming Catalysts (preview)

• Q1 2027IND filing for lead program (likely in a lysosomal storage disease)70% success
• Q3 2026Presentation of preclinical efficacy and capsid engineering data at a major conference90% success
• H1 2027Series C financing to support clinical development80% success